Effect of Neomycin on the Pharmacokinetics of Regorafenib
To investigate the effect of neomycin on the pharmacokinetics (PK) of regorafenib in healthy male subjects
Neoplasms
DRUG: Regorafenib (Stivarga, BAY73-4506)|DRUG: Neomycin
AUC (area under the plasma concentration vs. time curve) for regorafenib, Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, 144, 168 and 192 hours post-dose|Cmax (maximum drug concentration) for regorafenib, Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, 144, 168 and 192 hours post-dose
AUC(0-24) (area under the plasma concentration vs. time curve) for regorafenib, Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24 hours post-dose|AUC(0-tlast) (area under the plasma concentration vs. time curve) for regorafenib, Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, 144, 168 and 192 hours post-dose|AUC (area under the plasma concentration vs. time curve) for BAY75-7495 (M-2) and BAY81-8752 (M-5), Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, 144, 168 and 192 hours post-dose|Cmax (maximum drug concentration) for M-2 and M-5, Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, 144, 168 and 192 hours post-dose|tmax (time to reach maximum drug concentration in plasma after single dose) for regorafenib, M-2 and M-5, Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, 144, 168 and 192 hours post-dose|tlast (time of last concentration above lower limit of quantification) for regorafenib, M-2 and M-5, Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, 144, 168 and 192 hours post-dose|t1/2 (half-life associated with the terminal slope) for regorafenib, M-2 and M-5, Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, 144, 168 and 192 hours post-dose|AE,ur(0-72) (amount of drug excreted via urine during the collection interval 0-72 hours post administration) for metabolites BAY86-6651 (M-7) and BAY86-6652 (M-8), 0-72 hours post dose|Number of participants with adverse events as a measure of safety and tolerability, Up to 30 days after last dose
To investigate the effect of neomycin on the pharmacokinetics (PK) of regorafenib in healthy male subjects